Renal Physicians Association Participates in PEAK Campaign
...d Accountability in Kidney Care (PEAK) initiative. rpa is a member of KCP, a coalition which includes gro...mmend KCP for launching the PEAK initiative," said rpa President Dr. Edward Jones. "While the evidence b... in the overall improvement of CKD care quality." rpa has developed evidence-based clinical practice gui...PharmAthene Reports Year End 2008 Financial Results
...t contracts supporting the development of SparVax(TM), our third generation rpa anthrax vaccine candidate, and RypVax(TM). Research and development ex... - a recombinant dual antigen vaccine for plague A third generation rpa anthrax vaccine. For more information about PharmAthene, ...The Renal Physicians Guide to Nephrology Practice, 6th Edition
...nsure quality care under the highest standards of medical practice for patients with kidney disease and related disorders. For more information about rpa please visit www.renalmd.org or call 301-468-3515. ...Cogdell Spencer Breaks Ground on Projects in Tennessee and North Carolina
...cian groups. Erdman is the developer on the project, Robins & Morton of Birmingham, Alabama is the general contractor on this project while rpa Design, based in Charlotte, North Carolina, is the project architect on both the Tennessee and Mebane projects. Upon completion, Cogdell Spencer Inc....Renal Physicians Association 2009 Annual Meeting
...and relevant to today's nephrology practitioners. rpa will convene national leaders and experts in their... Beyond the rich and pertinent content that the rpa meeting offers, this unique venue allows nephrolog...rapple with every day. Register today for the 2009 rpa Annual Meeting March 20-23 in Baltimore, Maryland ...Iomai Wins Department of Defense Grant to Develop a Stable, Patch-Based Anthrax Vaccine
... UK site has been developing processes and making protein-based biopharmaceuticals to cGMP since 1998. Process development and cGMP manufacture of the rpa anthrax vaccine and the plague vaccine have been carried out at this site since 2000. Avecia Biotechnology Inc. is a leader in the field of contract m...PharmAthene Submits SparVax(TM) Regulatory Strategy to FDA
... and procure 25 million doses of a next generation rpa anthrax vaccine for the country's civilian biomedi...ced development and procurement of next generation rpa anthrax vaccines." About SparVax(TM) Spar...gen (rPA) anthrax vaccine Third generation rpa anthrax vaccine Valortim(R) - a fully huma...PharmAthene Initiates Phase I Clinical Trial of Nerve Agent Bioscavenger Protexia(R)
...t development programs include: -- SparVax(TM) - a second generation recombinant protective antigen (rPA) anthrax vaccine -- Third generation rpa anthrax vaccine -- Valortim(R) - a fully human monoclonal antibody for the prevention and treatment of anthrax infection -- Protexia(R) - a nove...ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
...s rPA102 anthrax vaccine is composed of a purified rpa and an aluminum salt adjuvant routinely used in ma...l be mirrored in testing of Viprovex with VaxGen's rpa antigen." Initial studies in a well-established m...chael Wilhelm. "With the previous success that the rpa vaccine has seen in the lab against anthrax we are...Kidney function discovery sheds light on genetic complexity of disease
... due to an inherited abnormality of a specific pump on the surface of kidney cells," Professor Rasko explains. The teams from Centenary Institute, rpa and ANU have now unravelled the genetic explanation by showing that not one, but up to four different pumps present in the kidney determine whether or...DNA ends: Common tool, different job
... Stn1, they dug up Rpa2, the middle subunit of the rpa complex. In particular, Stn1 and Rpa2 share simila...e just like their counterparts in the conventional rpa complex. However, Stn1 and Ten1 have the same pred...tial biological parallels between the conventional rpa complex and the newly discovered t-RPA complex. ...PharmAthene to Host Second Quarter 2009 Conference Call and Webcast on Thursday, August 13, 2009
...elopment programs include: SparVax(TM) -- a second generation recombinant protective antigen (rPA) anthrax vaccine Third generation rpa anthrax vaccine Valortim((R)) -- a fully human monoclonal antibody for the prevention and treatment of anthrax infection Protexia((R)) -- ...PharmAthene Reports First Quarter 2009 Financial and Operational Results
... activities related to the SparVax(TM), RypVax(TM) and our third generation rpa anthrax vaccine programs, which we acquired in the second quarter of 2008. ...combinant protective antigen (rPA) anthrax vaccine Third generation rpa anthrax vaccine Valortim(R) - a fully human monoclonal antibody for...PharmAthene Announces $5.5 Million Public Equity Offering
...t programs include: SparVax(TM) - a second generation recombinant protective antigen (rPA) anthrax vaccine Third generation rpa anthrax vaccine Valortim(R) - a fully human monoclonal antibody for the prevention and treatment of anthrax infection Protexia(R) - a ...PharmAthene To Host Year-End 2008 Earnings Conference Call and Webcast on Monday, March 30, 2009
...t programs include: SparVax(TM) - a second generation recombinant protective antigen (rPA) anthrax vaccine Third generation rpa anthrax vaccine Valortim(R) - a fully human monoclonal antibody for the prevention and treatment of anthrax infection Protexia(R) - a ...